Pawan Singh Karki

Pawan Singh Karki

Active Director Director DIN 09621144
DIN 09621144 First appointment May 2022 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2022
Shareholding value •••• Premium profile

About Pawan Singh Karki

Data last updated:

Pawan Singh Karki is a Director at Phymed Private Limited (since 2022). The company operates in Healthcare. Phymed Private Limited reported revenue of ₹4.11 Cr (FY 2025).

DIN 09621144
Primary Designation Director
Industry Healthcare
First Appointment 26 May 2022
Oldest Company Age 4 yrs
Largest company Phymed Private Limited · ₹4.11 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Phymed Private Limited U33110DL2022PTC399114
Director26 May 20222022₹4.11 Cr (FY 2025)Active

Board colleagues of Pawan Singh Karki

NameDINCompanyDesignation
Nikesh Kumar Singh09621143Phymed Private LimitedDirector

Directorship timeline

Open interactive timeline →
Phymed Private Limited
Premium access

Shareholding and investment profile for Pawan Singh Karki

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pawan Singh Karki

Pawan Singh Karki currently holds 1 directorship: Phymed Private Limited (Director, since 26 May 2022, revenue ₹4.11 Cr (FY 2025)).

Pawan Singh Karki was first appointed on 26 May 2022 as Director at Phymed Private Limited.

The current boards of Pawan Singh Karki's companies include Nikesh Kumar Singh (Phymed Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available